Jennifer La PhD
Adjunct Instructor, Hematology & Medical Oncology
72 E. Concord Street | (617) 638-7012jla2689@bu.edu
Sections
Hematology & Medical Oncology
Education
PhD, University of Chicago
MS, University of Chicago
Pharmacology, BS, Stony Brook University
Publications
Jose A, Lu S, Zhang C, La J, Young M, Gaziano JM, Fillmore NR, Ravid K, Chitalia VC. A panel of plasma proteins associated with venous thromboembolism in patients with prostate cancer. Cancer Biomark. 2025 Dec; 42(12):18758592251390251. PMID: 41348521.
Published on 11/3/2025Li A, Jafari O, Lam BD, Jiang JY, Kim RB, Ma S, Zhou E, Tiong JW, Chiang EC, Ryu J, Amos CI, La J, Fillmore NR. Validation of a Risk Score for Cancer-Associated Thrombosis Using Nationwide EHR Data. JAMA Netw Open. 2025 Nov 03; 8(11):e2544428. PMID: 41288979.
Published on 10/14/2025Lotfollahzadeh S, Jose A, Yang X, Bathla T, Lazowski A, Hoekstra I, Sethuraman K, Potluri S, Dulberger KN, La J, Fillmore NR, Piqueras MDC, Lee N, Cabral H, Ravid K, Chitalia VC. Dietary tryptophan augments cancer-associated venous thrombogenicity mitigated by indoleamine 2,3-dioxygenase 1 inhibition. Blood Adv. 2025 Oct 14; 9(19):4910-4923. PMID: 40668615.
Published on 9/1/2025La J, Hshieh T, Hamparsumian A, Zwolinski R, Wood J, Dharne M, Gaziano JM, Brophy MT, Do NV, Munshi NC, Driver JA, Abel GA, Fillmore NR, DuMontier C. Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System. J Natl Compr Canc Netw. 2025 Sep; 23(9):363-370. PMID: 40930142.
Published on 8/5/2025Jafari O, Ma S, Lam BD, Jiang JY, Zhou E, Ranjan M, Ryu J, Bandyo R, Maghsoudi A, Peng B, Amos CI, Oluyomi A, Fillmore NR, La J, Li A. Development and validation of venous thromboembolism-bidirectional encoder representations from transformers (VTE-BERT) natural language processing model. J Thromb Haemost. 2025 Aug 05. PMID: 40754035.
Published on 4/8/2025Lee MH, La J, Brophy MT, Do NV, Edwards CV, DuMontier C, Hobbs GS, Fillmore NR. Psychiatric and substance use disorders predict poor outcomes in older veterans with acute myeloid leukemia. Blood Adv. 2025 Apr 08; 9(7):1555-1558. PMID: 39715463.
Published on 4/1/2025Larsen JR, Zheng C, La J, Wu JT, Kelley M, Gaziano JM, Brophy M, Do NV, Kim DH, Driver JA, DuMontier C, Fillmore NR. Multimorbidity and Its Impact in Older U.S. Veterans Newly Treated for Advanced Non-Small Cell Lung Cancer. Ann Am Thorac Soc. 2025 Apr; 22(4):598-608. PMID: 39680869.
Published on 2/21/2025Swinnerton K, Fillmore NR, Vo A, La J, Elbers D, Brophy M, Do NV, Monach PA, Branch-Elliman W. Leveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool. EClinicalMedicine. 2025 Mar; 81:103114. PMID: 40070694.
Published on 2/3/2025Kim RB, Ryu JH, Guffey D, Zhou E, Ranjan M, Ma S, La J, Fillmore NR, Li A. Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system. J Thromb Haemost. 2025 May; 23(5):1539-1550. PMID: 39909143.
Published on 12/30/2024Wu JT, Corrigan J, Su C, Dumontier C, La J, Khan A, Arya S, Harris AHS, Backhus L, Das M, Do NV, Brophy MT, Han SS, Kelley M, Fillmore NR. Correction: The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2024 Dec 30; 74(1):34. PMID: 39739108.